Drug Repurposing for COVID-19: Current Status of Potential Therapeutics

References (142)

1. 1 Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor [DOI]
2. 2 Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan [DOI]
3. 3 Emerging coronaviruses: Genome structure, replication, and pathogenesis [DOI]
4. 4 Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods [DOI]
5. 5 Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19 [DOI]
6. 6 Baricitinib as potential treatment for 2019-nCoV acute respiratory disease [DOI]
7. 7 Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study [DOI]
8. 8 An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice [DOI]
9. 9 Favipiravir (T-705), a novel viral RNA polymerase inhibitor [DOI]
10. 10 Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro [DOI]
11. 11 Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update [DOI]
12. 12 The 2019‐new coronavirus epidemic: Evidence for virus evolution [DOI]
13. 13 Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France [DOI]
14. 14 Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With Coronavirus Disease 2019 (COVID-19; Metcovid): A Randomized, Double-blind, Phase IIb, Placebo-controlled Trial [DOI]
15. 15 Properties of Coronavirus and SARS-CoV-2.
16. 16 Coronavirus (COVID-19): A Review of Clinical Features, Diagnosis, and Treatment [DOI]
17. 17 Key cost drivers of pharmaceutical clinical trials in the United States [DOI]
18. 18 Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID‐19 [DOI]
19. 19 Small-Molecule Antiviral β- d - N 4 -Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance [DOI]
20. 20 The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro [DOI]
21. 21 Rapid repurposing of drugs for COVID-19 [DOI]
22. 22 Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitors [DOI]
23. 23 Azithromycin in the treatment of COVID-19: a review [DOI]
24. 24 Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study [DOI]
25. 25 Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study [DOI]
26. 26 Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID‐19 [DOI]
27. 27 An omics perspective on drug target discovery platforms [DOI]
28. 28 Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review [DOI]
29. 29 The anti‐HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV‐2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID‐19 infections [DOI]
30. 30 Therapeutic Potential for Tetracyclines in the Treatment of COVID‐19 [DOI]
31. 31 Macrolides and viral infections: focus on azithromycin in COVID-19 pathology [DOI]
32. 32 Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19? [DOI]
33. 33 Efficacy of Remdesivir in COVID-19 [DOI]
34. 34 Identification of a New Ribonucleoside Inhibitor of Ebola Virus Replication [DOI]
35. 35 Remdesivir in covid-19 [DOI]
36. 36 Treatment of Community-Acquired Pneumonia During the Coronavirus Disease 2019 (COVID-19) Pandemic [DOI]
37. 37 Successful use of methylprednisolone for treating severe COVID-19 [DOI]
38. 38 Drug repurposing against COVID-19: focus on anticancer agents [DOI]
39. 39 Ciprofloxacin and moxifloxacin could interact with SARS-CoV-2 protease: preliminary in silico analysis [DOI]
40. 40 Safety of corticosteroids in young children with acute respiratory conditions: a systematic review and meta-analysis [DOI]
41. 41 Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy [DOI]
42. 42 The HIV Protease Inhibitor Nelfinavir Downregulates Akt Phosphorylation by Inhibiting Proteasomal Activity and Inducing the Unfolded Protein Response [DOI]
43. 43 Protein localization vector propagation: a method for improving the accuracy of drug repositioning [DOI]
44. 44 Repurposing cefuroxime for treatment of COVID-19: a scoping review of in silico studies [DOI]
45. 45 Azithromycin and COVID‐19: Prompt early use at first signs of this infection in adults and children, an approach worthy of consideration [DOI]
46. 46 Aminoglycosides can be a better choice over macrolides in COVID-19 regimen: Plausible mechanism for repurposing strategy [DOI]
47. 47 Introduction to the Theme “New Therapeutic Targets” [DOI]
48. 48 Macrolide-Clarithromycin Task-Force for the Treatment and Prophylaxis of Covid-19 as a Single Agent [DOI]
49. 49 Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2 [DOI]
50. 50 The anti-HIV Drug Nelfinavir Mesylate (Viracept) is a Potent Inhibitor of Cell Fusion Caused by the SARS-CoV-2 Spike (S) Glycoprotein Warranting further Evaluation as an Antiviral against COVID-19 infections [DOI]
51. 51 Coronavirus biology and replication: implications for SARS-CoV-2 [DOI]
52. 52 Mechanisms of SARS-CoV-2 entry into cells [DOI]
53. 53 Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19 [DOI]
54. 54 Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19 [DOI]
55. 55 Drug repurposing approach to fight COVID-19 [DOI]
56. 56 Clinical manifestations of COVID-19 in the general population: systematic review [DOI]
57. 57 SARS-CoV-2 genomic and subgenomic RNAs in diagnostic samples are not an indicator of active replication [DOI]
58. 58 β- d - N 4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells [DOI]
59. 59 The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials [DOI]
60. 60 Dexamethasone for the Treatment of Coronavirus Disease (COVID-19): a Review [DOI]
61. 61 Improving target assessment in biomedical research: the GOT-IT recommendations [DOI]
62. 62 Clinical manifestation and disease progression in COVID-19 infection [DOI]
63. 63 The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19 [DOI]
64. 64 The Potential Intermediate Hosts for SARS-CoV-2 [DOI]
65. 65 Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action [DOI]
66. 66 Favipiravir and COVID-19: A Simplified Summary [DOI]
67. 67 Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID‐19 patients: A systematic review and meta‐analysis [DOI]
68. 68 Glycopeptide Antibiotic Teicoplanin Inhibits Cell Entry of SARS-CoV-2 by Suppressing the Proteolytic Activity of Cathepsin L [DOI]
69. 69 Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis [DOI]
70. 70 Marine sulfated polysaccharides as potential antiviral drug candidates to treat Corona Virus disease (COVID-19) [DOI]
71. 71 Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID‐19 [DOI]
72. 72 Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study [DOI]
73. 73 COVID-19 Pathogenesis and Clinical Manifestations [DOI]
74. 74 Repurposing of antibiotics for clinical management of COVID-19: a narrative review [DOI]
75. 75 Colchicine for the treatment of COVID-19 [DOI]
76. 76 Emetine suppresses SARS-CoV-2 replication by inhibiting interaction of viral mRNA with eIF4E [DOI]
77. 77 The ins and outs of SARS-CoV-2 variants of concern (VOCs) [DOI]
78. 78 Therapeutic role of corticosteroids in COVID-19: a systematic review of registered clinical trials [DOI]
79. 79 Nitazoxanide against COVID-19 in three explorative scenarios [DOI]
80. 80 Individualized therapy trials: navigating patient care, research goals and ethics [DOI]
81. 81 Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial [DOI]
82. 82 Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2? [DOI]
83. 83 Effect of early oseltamivir on outpatients without hypoxia with suspected COVID-19 [DOI]
84. 84 Drug repurposing in COVID-19: A review with past, present and future [DOI]
85. 85 A comprehensive review on sarilumab in COVID-19 [DOI]
86. 86 Aminoglycosides as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents [DOI]
87. 87 Can drug repurposing strategies be the solution to the COVID-19 crisis? [DOI]
88. 88 COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients [DOI]
89. 89 Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial [DOI]
90. 90 Low dose of emetine as potential anti-SARS-CoV-2 virus therapy: preclinical in vitro inhibition and in vivo pharmacokinetic evidences [DOI]
91. 91 Recent progress on the mutations of SARS-CoV-2 spike protein and suggestions for prevention and controlling of the pandemic [DOI]
92. 92 Spike glycoproteins: Their significance for corona viruses and receptor binding activities for pathogenesis and viral survival [DOI]
93. 93 Clinical efficacy of low-dose emetine for patients with COVID-19: a real-world study [DOI]
94. 94 Ruxolitinib and the Mitigation of Severe COVID-19: A Systematic Review and Meta-analysis [DOI]
95. 95 Efficacy of clarithromycin in patients with mild COVID-19 pneumonia not receiving oxygen administration: protocol for an exploratory, multicentre, open-label, randomised controlled trial (CAME COVID-19 study) [DOI]
96. 96 Glycopeptides as Potential Interventions for COVID-19 [DOI]
97. 97 Icatibant in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Case Report [DOI]
98. 98 Safety of protease inhibitors and Arbidol for SARS-CoV-2 pneumonia in Zhejiang Province, China [DOI]
99. 99 Adequate antibody response to BioNTech COVID vaccine in a multiple sclerosis patient treated with siponimod [DOI]
100. 100 Efficacy of Nitazoxanide in reducing the viral load in COVID-19 patients. Randomized, placebo-controlled, single-blinded, parallel group, pilot study. [DOI]
101. 101 Mutations and Evolution of the SARS-CoV-2 Spike Protein [DOI]
102. 102 Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay [DOI]
103. 103 Remdesivir for the treatment of COVID-19 [DOI]
104. 104 Efficacy of repurposed antiviral drugs: Lessons from COVID-19 [DOI]
105. 105 Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care [DOI]
106. 106 Understanding Mutations in Human SARS-CoV-2 Spike Glycoprotein: A Systematic Review & Meta-Analysis [DOI]
107. 107 Role of Dexamethasone and Methylprednisolone Corticosteroids in Coronavirus Disease 2019 Hospitalized Patients: A Review [DOI]
108. 108 Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity [DOI]
109. 109 Current evidence on the use of anakinra in COVID-19 [DOI]
110. 110 Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial [DOI]
111. 111 Remdesivir for the treatment of patients hospitalized with COVID-19 receiving supplemental oxygen: a targeted literature review and meta-analysis [DOI]
112. 112 A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study) [DOI]
113. 113 Colchicine use in patients with COVID-19: A systematic review and meta-analysis [DOI]
114. 114 Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease [DOI]
115. 115 Efficacy of oseltamivir in the treatment of patients infected with Covid-19 [DOI]
116. 116 The Quest for Secondary Pharmaceuticals: Drug Repurposing/Chiral-Switches Combination Strategy [DOI]
117. 117 Dexamethasone for Inpatients With COVID-19 in a National Cohort [DOI]
118. 118 Efficacy and Safety of Anakinra Plus Standard of Care for Patients With Severe COVID-19 [DOI]
119. 119 A Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Study To Evaluate the Efficacy and Safety of Camostat Mesylate (DWJ1248) in Adult Patients with Mild to Moderate COVID-19 [DOI]
120. 120 Efficacy of Colchicine in the Treatment of COVID-19 Patients: A Systematic Review and Meta-Analysis [DOI]
121. 121 The effect of Fingolimod on patients with moderate to severe COVID ‐19 [DOI]
122. 122 Three-Day Icatibant on Top of Standard Care in Patients With Coronavirus Disease 2019 Pneumonia: A Randomized, Open-Label, Phase 2, Proof-of-Concept Trial [DOI]
123. 123 The state of current research on COVID-19 and antibiotic use: global implications for antimicrobial resistance [DOI]
124. 124 Repurposing of drugs targeting the cytokine storm induced by SARS‐CoV‐2 [DOI]
125. 125 Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: a critical discussion of recent publications [DOI]
126. 126 Systematic review and meta-analysis of the efficacy and safety of oseltamivir (Tamiflu) in the treatment of Coronavirus Disease 2019 (COVID-19) [DOI]
127. 127 Preventive and therapeutic benefits of nelfinavir in rhesus macaques and human beings infected with SARS-CoV-2 [DOI]
128. 128 Pembrolizumab in combination with tocilizumab in high-risk hospitalized patients with COVID-19 (COPERNICO): A randomized proof-of-concept phase II study [DOI]
129. 129 Clinical efficacy of Azithromycin for COVID-19 management: A systematic meta-analysis of meta-analyses [DOI]
130. 130 Use of baricitinib in treatment of COVID‐19: a systematic review [DOI]
131. 131 Effects of bamlanivimab alone or in combination with etesevimab on subsequent hospitalization and mortality in outpatients with COVID-19: a systematic review and meta-analysis [DOI]
132. 132 Insights into the structural properties of SARS-CoV-2 main protease [DOI]
133. 133 A multicenter, open-label, randomized, proof-of-concept phase II clinical trial to assess the efficacy and safety of icatibant in patients infected with SARS-CoV-2 (COVID-19) and admitted to hospital units without invasive mechanical ventilation: study protocol (ICAT-COVID) [DOI]
134. 134 Effect of methylprednisolone treatment on COVID-19: An inverse probability of treatment weighting analysis [DOI]
135. 135 Emergence of Third Generation Tetracyclines: New Magic Bullets to Tackle Antibiotic Resistance in the Post-antibiotic Era [DOI]
136. 136 Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution [DOI]
137. 137 Favipiravir and/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE) [DOI]
138. 138 VACCINES VERSUS COVID-19 VACCINES: MANEUVER TIMELINE OF DEVELOPMENT AND TRIAL DESIGNS [DOI]
139. 139 Clinical profile of multisystem inflammatory syndrome in children associated with COVID-19 in a rural medical college [DOI]
140. 140 The World of Vaccines: Phases of Clinical Trials and Current Status of COVID-19 Vaccines [DOI]
141. 141 Publisher Correction: Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19 [DOI]
142. 142 Repurposing Remdesivir for COVID-19: Computational Drug Design Targeting SARS-CoV-2 RNA Polymerase and Main Protease using Molecular Dynamics Approach [DOI]

Cited by 0

No indexed citations yet.

Related research

• Antimicrobial Assessment of Annona muricata Fruits and Its Chemical Compositions — shares topic coverage
• Plasmid Profile of Multidrug Resistant Bacteria Isolated from Wound Swabs from Hospital Patients in Akure, Nigeria — shares topic coverage
• Molecular Detection of Extended Spectrum Beta-lactamase Resistance in Escherichia coli from Poultry Droppings in Keffi, Nigeria — shares topic coverage
• Microbiological Enumeration of Pathogens Associated with Urinary Tract Infection: Current Scenario and Its Medical Relevance — shares topic coverage
• Synergizing Bacteriophage Therapy and Computational Neuroscience: A Ray of Hope in the Fight against Antibiotic Resistance — shares topic coverage